Table 1.
Demographic and clinicopathological characteristics of the study population.
| Characteristic | Total (n = 83) | Group A—2020 (n = 42) |
Group B—2019 (n = 41) |
p Value |
|---|---|---|---|---|
| Age (mean ± SD) | 61.3 ± 12.6 | 62.0 ± 12.4 | 60.6 ± 13.9 | 0.62 |
| Tumour size (mean, SD) | 17.7 ± 10.0 | 16.4 ± 9.2 | 18.9 ± 10.7 | 0.25 |
| Tumour grade | 0.27 | |||
| I | 15 (18.1%) | 7 (17.1%) | 8 (19.0%) | |
| II | 48 (57.8%) | 27 (65.8%) | 21 (50.0%) | |
| III | 20 (24.1%) | 7 (17.1%) | 13 (31.0%) | |
| Tumor histology | 0.43 | |||
| IDC | 59 (71.2%) | 30 (73.2%) | 29 (69.0%) | |
| ILC | 12 (14.4) | 4 (9.7%) | 8 (19.0%) | |
| DCIS | 12 (14.4) | 7 (17.1%) | 5 (12.0) | |
| Positive Axillary lymph nodes | 11 (13.25%) | 4 (9.75%) | 7 (16.6%) | 0.35 |
| ER positive | 71 (85.5%) | 37 (90.2%) | 34 (80.9%) | 0.35 |
| Her2 positive | 12 (14.4%) | 5 (12.2%) | 7 (16.7%) | 0.75 |
| Neoadjuvant chemotherapy | 9 (10.8%) | 5 (12.2%) | 4 (9.5%) | 0.72 |
DCIS: Ductal carcinoma in situ; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma.